Biopharma Innovation in Respiratory Disease: Assessing AstraZeneca and Amgen's Tezspire in the CRSwNP Market

---

The approval of Tezspire (tezepelumab) by the U.S. Food and Drug Administration (FDA) in October 2025 for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) marks a pivotal moment in respiratory disease innovation. Developed by AstraZeneca and Amgen, Tezspire is the first and only biologic to target thymic stromal lymphopoietin (TSLP), a key cytokine in epithelial-driven inflammation, as detailed in an AstraZeneca press release. This mechanism differentiates it from existing therapies like Sanofi/Regeneron's Dupixent, which targets the IL-4/IL-13 axis. With the global CRSwNP market projected to grow from $5 billion in 2025 to $9 billion by 2033 at a 7% compound annual growth rate (CAGR), according to Data Insights Market, Tezspire's commercial potential is poised to reshape the competitive landscape.

Clinical Efficacy and Mechanistic Differentiation

Tezspire's approval was underpinned by the WAYPOINT Phase III trial, which demonstrated a statistically significant reduction in nasal polyp severity (-2.065 points on the total nasal polyp score) and nasal congestion (-1.028 points on the nasal congestion score) at week 52 compared to placebo, as shown in the WAYPOINT Phase III trial. The trial also showed a 98% reduction in the need for surgery and an 88% reduction in systemic corticosteroid use. These outcomes position Tezspire as a transformative therapy for patients with inadequately controlled CRSwNP, a condition affecting up to 320 million people globally, following the CHMP recommendation for EU approval.

The drug's upstream targeting of TSLP-a cytokine at the top of the inflammatory cascade-offers a novel approach compared to downstream IL-4/IL-13 or IL-5 inhibitors like Dupixent or GSK's depemokimab, as noted in a FiercePharma analysis. This mechanism may address unmet needs in patients who fail to respond to existing biologics, according to Amgen.

Market Dynamics and Growth Projections

The CRSwNP market is highly competitive, with Dupixent dominating due to its established efficacy in asthma and atopic dermatitis. However, Tezspire's unique mechanism and robust trial data could disrupt this dynamic. Analysts project Tezspire could achieve $3.6 billion in sales by 2030, driven by its expansion into CRSwNP and potential approvals in other TSLP-driven diseases, according to a CTOL analysis.

The European market further amplifies Tezspire's potential. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval for CRSwNP in September 2025, pending final EU Commission approval, as reported by Market Access Today. While pricing details remain undisclosed, the drug's cost-effectiveness in reducing hospital visits and corticosteroid use could bolster payer adoption.

Pricing, Reimbursement, and Competitive Challenges

In the U.S., Tezspire carries a list price of $4,368.96 per 210 mg/mL syringe, with co-pay assistance programs reducing out-of-pocket costs for insured patients, as detailed on the cost and affordability page. However, reimbursement hurdles persist. Ireland's National Centre for Pharmacoeconomics (NCPE) recently declined Tezspire for reimbursement in severe asthma for patients with low eosinophil levels, citing cost-effectiveness concerns, according to Ireland's NCPE. Such challenges highlight the need for AstraZeneca and Amgen to negotiate favorable pricing with payers, particularly in the EU.

Dupixent, with global sales of €10.7 billion in 2024, according to an EulerPool report, remains a formidable competitor. Yet, Tezspire's trial results-showing superior reductions in nasal polyp scores compared to Dupixent's historical data-could justify its premium pricing in markets prioritizing clinical outcomes, as noted by FiercePharma.

Strategic Positioning for AstraZeneca and Amgen

AstraZeneca and Amgen's joint commercialization strategy in North America, combined with regulatory applications in China, Japan, and other regions, underscores their commitment to maximizing Tezspire's global footprint, as reported by Pulmonology Advisor. The partnership's shared infrastructure and co-promotion rights provide a scalable model for market penetration.

However, long-term success will depend on securing formulary access and demonstrating value in real-world settings. Analysts emphasize that Tezspire's ability to reduce surgical interventions and corticosteroid dependency-key cost drivers in CRSwNP-could offset its high list price, per the CTOL analysis.

Investment Outlook

Tezspire represents a paradigm shift in respiratory biologics, leveraging a first-in-class mechanism to address a high-unmet-need patient population. While pricing and reimbursement challenges remain, the drug's clinical differentiation and favorable trial outcomes position it to capture significant market share. For investors, AstraZeneca and Amgen's strategic execution in navigating payer dynamics and expanding Tezspire's indications will be critical watchpoints.

---